Register Login

MILESTONE PHARMACEUTICALS INC. (MIST)

SymbolMIST
NameMILESTONE PHARMACEUTICALS INC.
SectorHEALTH CARE
RegionNorth America
IndustryBiotechnology: Pharmaceutical Preparations
Address1111 DR. FREDERIK-PHILIPS BOULEVARD,SUITE 420, MONTREAL, Quebec, H4M 2X6, Canada
Telephone+1 514 336-0444
Fax—
Email—
Websitehttps://www.milestonepharma.com
IncorporationUNDEFINED
Incorporated On—
Employees—
Fiscal Year—
Public Since—
ExchangesNASDAQ
Auditor—
Audit StatusNOT PROVIDED
Reporting Status—
CIK0001408443
Description

Milestone Pharmaceuticals Inc is a biopharmaceutical company dedicated to developing and commercializing etripamil for the treatment of cardiovascular indications.

Additional info from NASDAQ:
Milestone Pharmaceuticals Inc is a biopharmaceutical company dedicated to developing and commercializing etripamil for the treatment of cardiovascular indications.

2026-07-03 01:30

Milestone Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Read more
2026-06-12 20:15

Giles Lisa M. 🟢 acquired 77.0K shares (1 derivative) of Milestone Pharmaceuticals Inc. (MIST) at $1.22 Transaction Date: Jun 10, 2026 | Filing ID: 000002

Read more
2026-06-12 20:15

Fischer Seth H. Z. 🟢 acquired 77.0K shares (1 derivative) of Milestone Pharmaceuticals Inc. (MIST) at $1.22 Transaction Date: Jun 10, 2026 | Filing ID: 000002

Read more
2026-06-12 20:15

Duty Stuart 🟢 acquired 77.0K shares (1 derivative) of Milestone Pharmaceuticals Inc. (MIST) at $1.22 Transaction Date: Jun 10, 2026 | Filing ID: 000004

Read more
2026-06-12 20:15

Wills Robert James 🟢 acquired 77.0K shares (1 derivative) of Milestone Pharmaceuticals Inc. (MIST) at $1.22 Transaction Date: Jun 10, 2026 | Filing ID: 000002

Read more
2026-06-12 20:15

TOMSICEK MICHAEL JOHN 🟢 acquired 77.0K shares (1 derivative) of Milestone Pharmaceuticals Inc. (MIST) at $1.22 Transaction Date: Jun 10, 2026 | Filing ID: 000003

Read more
2026-06-12 20:15

Saik Andrew 🟢 acquired 77.0K shares (1 derivative) of Milestone Pharmaceuticals Inc. (MIST) at $1.22 Transaction Date: Jun 10, 2026 | Filing ID: 000002

Read more
2026-06-12 20:15

PAPA JOSEPH C 🟢 acquired 77.0K shares (1 derivative) of Milestone Pharmaceuticals Inc. (MIST) at $1.22 Transaction Date: Jun 10, 2026 | Filing ID: 000014

Read more
2026-05-26 07:03

New Form EFFECT - Milestone Pharmaceuticals Inc. <b>Filed:</b> 2026-05-22 <b>AccNo:</b> 9999999995-26-001747 <b>Size:</b> 1 KB

Read more
2026-05-15 09:26

New Form SCHEDULE 13G/A - Milestone Pharmaceuticals Inc. <b>Filed:</b> 2026-05-15 <b>AccNo:</b> 0001493215-26-000112 <b>Size:</b> 11 KB

Read more
Trial ID Title Phase Indication Status Start Date Completion Date Source
NCT06716021 ReVeRA-301: Etripamil in Atrial Fibrillation Phase 3 Phase3 Atrial Fibrillation Not_Yet_Recruiting 2027-01-01 2030-01-01 ClinicalTrials.gov
NCT05763953 The NODE-202 Study (Study of Etripamil Nasal Spray in Pediatric Patients) Phase2 Paroxysmal Supraventricular Tachycardia Recruiting 2023-12-11 2027-06-30 ClinicalTrials.gov
NCT05511870 A Study of Etripamil in Healthy Subjects Phase1 Healthy Chinese Subjects Completed 2023-03-07 2023-03-26 ClinicalTrials.gov
NCT05410860 Efficacy and Safety Study of Etripamil Nasal Spray Self-Administration for the … Phase3 Tachycardia, Supraventricular Completed 2022-06-30 2024-12-10 ClinicalTrials.gov
NCT04952610 Etripamil Nasal Spray in Patients With Paroxysmal Supraventricular Tachycardia Phase3 Paroxysmal Supraventricular Tachycardia Completed 2021-12-13 2026-04-10 ClinicalTrials.gov
NCT04467905 ReVeRA-201: Etripamil in Atrial Fibrillation, Phase 2 Phase2 Atrial Fibrillation Completed 2020-11-19 2023-08-10 ClinicalTrials.gov
NCT04072835 Safety Study of Etripamil Nasal Spray for Patients With Paroxysmal Supraventric… Phase3 Paroxysmal Supraventricular Tachycardia Completed 2019-09-23 2023-01-26 ClinicalTrials.gov
NCT03635996 Safety Study of Intranasal Etripamil for the Termination of Spontaneous Episode… Phase3 Paroxysmal Supraventricular Tachycardia Terminated 2018-12-10 2020-11-13 ClinicalTrials.gov
NCT03464019 Efficacy and Safety of Etripamil for the Termination of Spontaneous Paroxysmal … Phase3 Paroxysmal Supraventricular Tachycardia Terminated 2018-06-18 2023-01-20 ClinicalTrials.gov
NCT03920345 Endoscopic Electrothermic Procedure of the Sacroiliac Joint Na Chronic Lower Back Pain (CLBP) Terminated 2018-06-08 2019-05-16 ClinicalTrials.gov
NCT03353610 The PSVT Place Registry.Paroxysmal Supraventricular Tachycardia (PSVT) Registry. — Paroxysmal Supraventricular Tachycardia (PSVT) Terminated 2017-10-16 2020-03-16 ClinicalTrials.gov
NCT02982226 ReNu™ vs. Corticosteroids for the Treatment of Plantar Fasciitis Na Fasciitis, Plantar Unknown 2016-09-01 2021-04-01 ClinicalTrials.gov
NCT02296190 Efficacy and Safety of Intranasal MSP-2017 (Etripamil) for the Conversion of PS… Phase2 Paroxysmal Supraventricular Tachycardia (PSVT) Completed 2015-03-27 2016-12-01 ClinicalTrials.gov
Total clinical trials: 13
Product Name Type Development Stage Therapeutic Area Study Status Trial ID
Aptar Pharma Nasal Spray Bidose System Other Phase PHASE3 Paroxysmal Supraventricular Tachycardia COMPLETED NCT04952610
Etripamil NS 70 mg Other Phase PHASE3 Paroxysmal Supraventricular Tachycardia COMPLETED NCT04952610
Aptar Pharma Nasal Spray Bidose System Other Phase PHASE3 Paroxysmal Supraventricular Tachycardia COMPLETED NCT04952610
Etripamil NS 70 mg Other Phase PHASE3 Paroxysmal Supraventricular Tachycardia COMPLETED NCT04952610
Aptar Pharma Nasal Spray Bidose System Other Phase PHASE3 Paroxysmal Supraventricular Tachycardia COMPLETED NCT04952610
Etripamil NS 70 mg Other Phase PHASE3 Paroxysmal Supraventricular Tachycardia COMPLETED NCT04952610
Aptar Pharma Nasal Spray Bidose System Other Phase PHASE3 Paroxysmal Supraventricular Tachycardia COMPLETED NCT04952610
Etripamil NS 70 mg Other Phase PHASE3 Paroxysmal Supraventricular Tachycardia COMPLETED NCT04952610
Aptar Pharma Nasal Spray Bidose System Other Phase PHASE3 Paroxysmal Supraventricular Tachycardia COMPLETED NCT04952610
Etripamil NS 70 mg Other Phase PHASE3 Paroxysmal Supraventricular Tachycardia COMPLETED NCT04952610
Aptar Pharma Nasal Spray Bidose System Other Phase PHASE3 Paroxysmal Supraventricular Tachycardia COMPLETED NCT04952610
Etripamil NS 70 mg Other Phase PHASE3 Paroxysmal Supraventricular Tachycardia COMPLETED NCT04952610
Aptar Pharma Nasal Spray Bidose System Other Phase PHASE3 Paroxysmal Supraventricular Tachycardia COMPLETED NCT04952610
Etripamil NS 70 mg Other Phase PHASE3 Paroxysmal Supraventricular Tachycardia COMPLETED NCT04952610
Aptar Pharma Nasal Spray Bidose System Other Phase PHASE3 Paroxysmal Supraventricular Tachycardia COMPLETED NCT04952610
Etripamil NS 70 mg Other Phase PHASE3 Paroxysmal Supraventricular Tachycardia COMPLETED NCT04952610
MultiZYTE Other Approved Chronic Lower Back Pain (CLBP) TERMINATED NCT03920345
Corticosteroid Injection Other Approved Fasciitis, Plantar UNKNOWN NCT02982226
ReNu Injection Other Approved Fasciitis, Plantar UNKNOWN NCT02982226
Placebo Other Phase PHASE2 Paroxysmal Supraventricular Tachycardia (PSVT) COMPLETED NCT02296190
Etripamil Other Phase PHASE2 Paroxysmal Supraventricular Tachycardia (PSVT) COMPLETED NCT02296190
Placebo Other Phase PHASE1 Healthy Chinese Subjects COMPLETED NCT05511870
Etripamil Nasal Spray 70mg Other Phase PHASE1 Healthy Chinese Subjects COMPLETED NCT05511870
Etripamil NS Other Phase PHASE3 Paroxysmal Supraventricular Tachycardia COMPLETED NCT04072835
Etripamil Test Dose Other Phase PHASE3 Paroxysmal Supraventricular Tachycardia TERMINATED NCT03464019
Placebo Other Phase PHASE3 Paroxysmal Supraventricular Tachycardia TERMINATED NCT03464019
Etripamil Other Phase PHASE3 Paroxysmal Supraventricular Tachycardia TERMINATED NCT03464019
Placebo Other Phase PHASE2 Atrial Fibrillation COMPLETED NCT04467905
Etripamil Other Phase PHASE2 Atrial Fibrillation COMPLETED NCT04467905
Aptar Pharma Nasal Spray Bidose System Other Phase PHASE3 Paroxysmal Supraventricular Tachycardia TERMINATED NCT03635996
Etripamil NS 70 mg Other Phase PHASE3 Paroxysmal Supraventricular Tachycardia TERMINATED NCT03635996
Placebo Other Phase PHASE3 Tachycardia, Supraventricular COMPLETED NCT05410860
Etripamil NS 70 mg Other Phase PHASE3 Tachycardia, Supraventricular COMPLETED NCT05410860
Etripamil NS Other Phase PHASE2 Paroxysmal Supraventricular Tachycardia RECRUITING NCT05763953
Aptar Pharma Nasal Spray Bidose System Other Phase PHASE3 Paroxysmal Supraventricular Tachycardia ENROLLING_BY_INVITATION NCT04952610
Etripamil NS 70 mg Other Phase PHASE3 Paroxysmal Supraventricular Tachycardia ENROLLING_BY_INVITATION NCT04952610
Etripamil Nasal Spray 70mg DRUG Phase PHASE1 Healthy Chinese Subjects COMPLETED NCT05511870
Etripamil NS DRUG Phase PHASE2 Paroxysmal Supraventricular Tachycardia RECRUITING NCT05763953
Aptar Pharma Nasal Spray Bidose System DEVICE Phase PHASE3 Paroxysmal Supraventricular Tachycardia ENROLLING_BY_INVITATION NCT04952610
Etripamil NS 70 mg DRUG Phase PHASE3 Tachycardia, Supraventricular COMPLETED NCT05410860
Etripamil Test Dose DRUG Phase PHASE3 Paroxysmal Supraventricular Tachycardia TERMINATED NCT03464019
Placebo DRUG Phase PHASE3 Atrial Fibrillation NOT_YET_RECRUITING NCT06716021
Etripamil DRUG Phase PHASE3 Atrial Fibrillation NOT_YET_RECRUITING NCT06716021
Total products: 43